Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation
Open accessAbstract
Aggregation of recombinant AAV2 results in reduced yield during purification and may have deleterious effects on vector transduction efficiency, biodistribution and immunogenicity following in vivo administration. Studies to elucidate the mechanism of vector aggregation and methods to prevent its occurrence are reported. In excipient screening studies, the sugars sorbitol, sucrose, mannitol, trehalose, or glycerol at concentrations of up to 5% (w/v), or surfactants Tween 80 or Pluronic F68, did not prevent aggregation. Aggregation was prevented by the use of various salts at concentrations corresponding to solution ionic strengths of >200 mM. AAV2 vectors purified by double cesium chloride gradient centrifugation, cation-exchange chromatography, or combined chromatography and gradient centrifugation each demonstrated a similar requirement for ionic strength to prevent aggregation. AAV2 vectors concentrated to 6.7 x 10(13) vector genome (vg)/mL in neutral-buffered isotonic saline resulted in 59+/-6.0% recovery of nonaggregated material compared to 96+/-4.4% recovery in an isotonic formulation with elevated ionic strength. The latter showed no aggregation following storage or after 10 freeze-thaw cycles at -20 degrees C. AAV2 vectors stored for an extended period in an elevated ionic strength formulation retained a high infectivity titer (13 vg/infectious unit) and transduction efficiency. Nuclease digestion of purified AAV2 vectors reduced aggregation, implicating trace amounts of vector surface nucleic acids in interparticle binding.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Capsids tend to aggregate depending on their total concentration and environmental conditions such as temperature, ionic strength, and pH.
“Moreover, capsids tend to aggregate depending on their total concentration and environmental conditions, such as the temperature, ionic strength, and pH.36”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [36]
High concentration of capsids, residual nucleic acids, or low ionic strength in the sample matrix were shown to contribute to aggregation of rAAV2.
“and high concentration of capsids, residual nucleic acids, or a low ionic strength in the sample matrix were shown to contribute to aggregation of rAAV2.36”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Instability, stabilization, and formulation of liquid protein pharmaceuticals
Wang, W. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00152-0 · Cited by 1,070 · see citing works
Challenges in the development of high protein concentration formulations
Shire, S. J., Shahrokh, Z., & 刘, J. 军. L. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20079 · Cited by 886 · see citing works
Challenges in the Development of High Protein Concentration Formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2009) · Springer eBooks · doi:10.1007/978-0-387-76643-0_9 · Cited by 657 · see citing works
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · see citing works
Adeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 507 · see citing works
Gene Therapy: Promises and Problems
Pfeifer, A., & Verma, I. M. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.177 · Cited by 344 · see citing works
Braun, A. B., Kwee, L., Labow, M., & Alsenz, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012193326789 · Cited by 299 · see citing works
Quantification of adeno-associated virus particles and empty capsids by optical density measurement
Sommer, J. Ü. M., Smith, P. H., Parthasarathy, S., Isaacs, J., Vijay, S., Kieran, J., Powell, S. K., McClelland, A., & Wright, J. F. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00019-9 · Cited by 230 · see citing works
Self-citationDevelopment of formulations that enhance physical stability of viral vectors for gene therapy
Croyle, M., Cheng, X., & Wilson, J. M. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301527 · Cited by 189 · see citing works
Erythropoietin gene therapy leads to autoimmune anemia in macaques
Gao, G., Lebherz, C., Weiner, D. J., Grant, R. L., Calcedo, R., McCullough, B. A., Bagg, A., Zhang, Y., & Wilson, J. M. (2003) · Blood · doi:10.1182/blood-2003-11-3852 · Cited by 156 · see citing works
Progress in Adeno-Associated Virus Type 2 Vector Production: Promises and Prospects for Clinical Use
Grimm, D., & Kleinschmidt, J. A. (1999) · Human Gene Therapy · doi:10.1089/10430349950016799 · Cited by 123 · see citing works
Autoimmune anemia in macaques following erythropoietin gene therapy
Chenuaud, P., Larcher, T., Rabinowitz, J. E., Provost, N., Chérel, Y., Casadevall, N., Samulski, R. J., & Moullier, P. (2004) · Blood · doi:10.1182/blood-2003-11-3845 · Cited by 116 · see citing works
Flotte, T. R. (2004) · Human Gene Therapy · doi:10.1089/1043034041361190 · Cited by 91 · see citing works
Chen, B., Arakawa, T., Hsu, E., Narhi, L. O., Tressel, T. J., & Chien, S. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600831204 · Cited by 82 · see citing works
Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.
Jf, W., Qu, G., Tang, C., & Sommer, J. M. (2003) · PubMed · Cited by 81 · see citing works
Self-citationAAV‐Mediated Gene Transfer for Hemophilia
High, K. A. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb11361.x · Cited by 56 · see citing works
Large-scale production, purification and crystallization of wild-type adeno-associated virus-2
Xie, Q., Hare, J. T., Turnigan, J., & Chapman, M. S. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.07.007 · Cited by 56 · see citing works
Zhen, Z., Espinoza, Y., Bleu, T., Sommer, J. M., & Wright, J. F. (2004) · Human Gene Therapy · doi:10.1089/1043034041361262 · Cited by 51 · see citing works
Self-citationWon, C. M., Molnar, T. E., McKean, R. E., & Spenlehauer, G. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00038-6 · Cited by 37 · see citing works
High, K. A., Tigges, M. A., Manno, C. S., Sabatino, D. E., Arruda, V. R., Herzog, R. W., Rustagi, P. K., Rasko, J. E. J., Sommer, J. M., Jaworski, K., et al. (2004) · Blood · doi:10.1182/blood.v104.11.413.413 · Cited by 14 · see citing works
Self-citation(2003) · Molecular Therapy · doi:10.1016/s1525-0016(16)41342-0 · Cited by 12 · see citing works
A Short-Term Field Use and Shipping Stability Study of a Wild Type Ad5 Adenoviral Reference Material
Bowe, M. A., Adadevoh, K., Croyle, M. A., Malarme, D., & Bonfils, E. (2002) · BioProcessing Journal · doi:10.12665/j13.bowe · Cited by 9 · see citing works
(2003) · Molecular Therapy · doi:10.1016/s1525-0016(16)41343-2 · Cited by 7 · see citing works
Flagged first, then by citations
1 of the 24 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- [4]4. Berns, K.I. Parvoviridae: the viruses and their replication Fields, B.N. ∙ Knipe, D.M. ∙ Howley, P.M. ... (Editors) Fields Virology Lippincott–Raven, Philadelphia, 1996; 2173-2197 Google Scholar
- [7]7. Huang, J. ... Aggregation of AAV vectors, its impact on liver directed gene transfer and development of vector formulations to prevent and dissolve aggregation and enhance gene transfer efficiency Mol. Ther. 2000; 1:S286 Google Scholar
Cited by
Sorted by citations
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · see citing works
Self-citationRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · see citing works
Self-citationHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762 · see citing works
Self-citationAntibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545 · see citing works
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · see citing works
Self-citationRapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
Lock, M. W., Alvira, M. R., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.055 · Cited by 328 · see citing works
Ayuso, E., Mingozzi, F., Montané, J., León, X., Anguela, X. M., Haurigot, V., Edmonson, S. A., Africa, L. M., Zhou, S., High, K. A., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.157 · Cited by 279 · see citing works
Self-citationManufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269 · see citing works
Assessing the potential for AAV vector genotoxicity in a murine model
Li, H., Malani, N., Hamilton, S. R., Schlachterman, A., Bussadori, G., Edmonson, S. A., Shah, R., Arruda, V. R., Mingozzi, F., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2010-08-302729 · Cited by 234 · see citing works
Self-citationPharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213 · see citing works
Manufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205 · see citing works
Self-citationGimpel, A. L., Katsikis, G., Sha, S., Maloney, A. J., Hong, M. S., Nguyen, T. N. T., Wolfrum, J., Springs, S. L., Sinskey, A. J., Manalis, S. R., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.010 · Cited by 185 · see citing works
Tung, Y.-C., Ayuso, E., Shan, X., Bosch, F., O’Rahilly, S., Coll, A. P., & Yeo, G. S. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008771 · Cited by 180 · see citing works
Pharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177 · see citing works
Qu, G., Bahr-Davidson, J., Prado, J., Tai, A., Cataniag, F., McDonnell, J., Zhou, J.-M., Hauck, B., Luna, J., Sommer, J. M., et al. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.11.019 · Cited by 156 · see citing works
Self-citationApplications of Charge Detection Mass Spectrometry in Molecular Biology and Biotechnology
Jarrold, M. F. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00377 · Cited by 156 · see citing works
Liguore, W. A., Domire, J. S., Button, D. A., Wang, Y., Dufour, B. D., Srinivasan, S., & McBride, J. L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.017 · Cited by 148 · see citing works
Evaluation of nanoparticle tracking analysis for total virus particle determination
Kramberger, P., Ciringer, M., Štrancar, A., & Peterka, M. (2012) · Virology Journal · doi:10.1186/1743-422x-9-265 · Cited by 112 · see citing works
Dika, C., Duval, J. F. L., Ly-Chatain, H. M., Merlin, C., & Gantzer, C. (2011) · Applied and Environmental Microbiology · doi:10.1128/aem.00407-11 · Cited by 97 · see citing works
Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89 · see citing works
Hauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88 · see citing works
Self-citationEnhanced Real-Time Monitoring of Adeno-Associated Virus Trafficking by Virus–Quantum Dot Conjugates
Joo, K., Fang, Y. H., Liu, Y., Liang, X., Gu, Z., Tai, A., Lee, C.-L., Tang, Y., & Wang, P. (2011) · ACS Nano · doi:10.1021/nn102651p · Cited by 88 · see citing works
Barnes, L. F., Draper, B. E., Chen, Y., Powers, T. W., & Jarrold, M. F. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.08.002 · Cited by 85 · see citing works
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 78 · see citing works
Adams, B., Bak, H., & Tustian, A. D. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27472 · Cited by 72 · see citing works
Hutton-Smith, L. A., Gaffney, E. A., Byrne, H. M., Maini, P. K., Gadkar, K. G., & Mazer, N. A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00164 · Cited by 71 · see citing works
Vicente, T., Mota, J. P. B., Peixoto, C., Alves, P. M., & Carrondo, M. J. T. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.07.004 · Cited by 69 · see citing works
Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model
Suhy, D. A., Kao, S.-C., Mao, T. K., Whiteley, L. O., Denise, H., Souberbielle, B. E., Burdick, A. D., Hayes, K., Wright, J. F., Lavender, H., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.119 · Cited by 59 · see citing works
Self-citationProduction and Discovery of Novel Recombinant Adeno‐Associated Viral Vectors
Mueller, C., Ratner, D., Li, Z., Sena‐Esteves, M., & Gao, G. (2012) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc14d01s26 · Cited by 57 · see citing works
Materials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 56 · see citing works
Site‐Specific Modification of Adeno‐Associated Viruses via a Genetically Engineered Aldehyde Tag
Liu, Y., Fang, Y. H., Zhou, Y., Zandi, E., Lee, C.-L., Joo, K., & Wang, P. (2012) · Small · doi:10.1002/smll.201201661 · Cited by 55 · see citing works
Assessment of quality attributes for adeno‐associated viral vectors
Tustian, A. D., & Bak, H. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27905 · Cited by 53 · see citing works
Potency testing of cell and gene therapy products
Salmikangas, P., Carlsson, B., Klumb, C., Reimer, T., & Thirstrup, S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1190016 · Cited by 51 · see citing works
Dika, C., Gantzer, C., Perrin, A., & Duval, J. F. L. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp44128h · Cited by 45 · see citing works
Host and Vector-dependent Effects on the Risk of Germline Transmission of AAV Vectors
Favaro, P. M. B., Downey, H. D., Zhou, J. S., Wright, J. F., Hauck, B., Mingozzi, F., High, K. A., & Arruda, V. R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.56 · Cited by 40 · see citing works
Self-citationKhanal, O., Kumar, V., & Jin, M. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101112 · Cited by 39 · see citing works
Wu, T.-L., Li, H., Faust, S. M., Chi, E., Zhou, S., Wright, F., High, K. A., & Ertl, H. C. (2014) · Molecular Therapy · doi:10.1038/mt.2013.218 · Cited by 38 · see citing works
Self-citationTreatment to cure: Advancing AAV gene therapy manufacture
Young, P. M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103610 · Cited by 38 · see citing works
The ice age – A review on formulation of Adeno-associated virus therapeutics
Grossen, P., Skaripa-Koukelli, I., van Haasteren, J., Machado, A. H. E., & Dürr, C. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.07.002 · Cited by 36 · see citing works
Manufacturing of viral vectors: part II. Downstream processing and safety aspects
Merten, O.-W., Schweizer, M., Chahal, P. S., & Kamen, A. (2014) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.14.15 · Cited by 33 · see citing works
Madrigal, J. L., Shams, S., Stilhano, R. S., & Silva, E. A. (2018) · Biomaterials Science · doi:10.1039/c8bm01218k · Cited by 29 · see citing works
Maruno, T., Ishii, K., Torisu, T., & Uchiyama, S. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.10.023 · Cited by 28 · see citing works
Chen, F., Tan, Z., Dong, C., Li, X., Xie, Y., Wu, Y., Chen, X., & Shu-fang, G. U. O. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.04.047 · Cited by 28 · see citing works
Biomaterial-Guided Gene Delivery for Musculoskeletal Tissue Repair
Madrigal, J. L., Stilhano, R. S., & Silva, E. A. (2017) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2016.0462 · Cited by 28 · see citing works
Tanaka, T., Hanaoka, H., & Sakurai, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.002 · Cited by 27 · see citing works
Chen, H. (2007) · Microscopy and Microanalysis · doi:10.1017/s1431927607070808 · Cited by 26 · see citing works
Development of a stable lyophilized adeno-associated virus gene therapy formulation
Zhang, Y., DePaz, R. A., Bee, J. S., & Marshall, T. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120912 · Cited by 25 · see citing works
Kellish, P. C., Marsic, D., Crosson, S. M., Choudhury, S., Scalabrino, M. L., Strang, C. E., Hill, J. L., McCullough, K. T., Peterson, J. J., Fajardo, D. S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.001 · Cited by 25 · see citing works
Lytle, A. M., Brown, H. C., Paik, N. Y., Knight, K. A., Wright, J. F., Spencer, H. T., & Doering, C. B. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.56 · Cited by 25 · see citing works
Self-citationKey considerations in formulation development for gene therapy products
Mohammad, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.013 · Cited by 24 · see citing works
Gränicher, G., Babakhani, M., Göbel, S., Jordan, I., Marichal‐Gallardo, P., Genzel, Y., & Reichl, U. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27937 · Cited by 24 · see citing works
Systematic Studies on Stabilization of AAV Vector Formulations by Lyophilization
Rieser, R., Menzen, T., Biel, M., Michalakis, S., & Winter, G. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.03.004 · Cited by 24 · see citing works
Field-Flow Fractionation in Molecular Biology and Biotechnology
Giordani, S., Marassi, V., Placci, A., Zattoni, A., Roda, B., & Reschiglian, P. (2023) · Molecules · doi:10.3390/molecules28176201 · Cited by 24 · see citing works
McNally, D. J., Piras, B. A., Willis, C., Lockey, T. D., & Meagher, M. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.015 · Cited by 23 · see citing works
Bee, J. S., Zhang, Y., Phillippi, M. K., Finkner, S., Mezghebe, T., Webber, K., Cheung, W. D., & Marshall, T. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.01.002 · Cited by 23 · see citing works
Chan, A., Maturana, C. J., & Engel, E. A. (2022) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114598 · Cited by 23 · see citing works
Meierrieks, F., Pickl, A., & Wolff, M. W. (2023) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2023.03.010 · Cited by 23 · see citing works
Lavoie, R. A., Zugates, J. T., Cheeseman, A. T., Teten, M. A., Ramesh, S., Freeman, J. M., Swango, S., Fitzpatrick, J., Joshi, A., Hollers, B. C., et al. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28453 · Cited by 23 · see citing works
Rieser, R., Penaud‐Budloo, M., Bouzelha, M., Rossi, A., Menzen, T., Biel, M., Büning, H., Ayuso, E., Winter, G., & Michalakis, S. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.031 · Cited by 23 · see citing works
Opportunities to debottleneck the downstream processing of the oncolytic measles virus
Loewe, D., Dieken, H., Grein, T. A., Weidner, T., Salzig, D., & Czermak, P. (2020) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2019.1709794 · Cited by 23 · see citing works
Hiemenz, C., Pacios-Michelena, A., Helbig, C., Vezočnik, V., Strebl, M., Nikels, F., Hawe, A., Garidel, P., & Menzen, T. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.009 · Cited by 22 · see citing works
Chen, D. P., Wei, J. Y., Warren, J. C., & Huang, C. (2023) · Biotechnology Journal · doi:10.1002/biot.202300063 · Cited by 22 · see citing works
Ultrafiltration behavior of recombinant adeno associated viral vectors used in gene therapy
Arunkumar, A., & Singh, N. (2020) · Journal of Membrane Science · doi:10.1016/j.memsci.2020.118812 · Cited by 22 · see citing works
Quality control and analytical methods for baculovirus-based products
Roldão, A., Vicente, T., Peixoto, C., Carrondo, M. J. T., & Alves, P. M. (2011) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2011.05.009 · Cited by 22 · see citing works
Bevaart, L., Aalbers, C. J., Vierboom, M., Broekstra, N., Kondova, I. I., Breedveld, E., Hauck, B., Wright, J. F., Tak, P. P., & Vervoordeldonk, M. J. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/hum.2015.009 · Cited by 20 · see citing works
Self-citationFeng, C. H. E. N., Tan, Z., Dong, C., Chen, X., & Shu-fang, G. U. O. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00527.x · Cited by 20 · see citing works
Katsikis, G., Hwang, I. E., Wang, W., Bhat, V. S., McIntosh, N. L., Karim, O. A., Blus, B. J., Sha, S., Agache, V., Wolfrum, J. M., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c04092 · Cited by 19 · see citing works
Sternberg, A. R., Martos-Rus, C., Davidson, R. J., Liu, X., & George, L. A. (2024) · Nature Communications · doi:10.1038/s41467-024-51296-8 · Cited by 19 · see citing works
Lorek, J. K., Isaksson, M., & Nilsson, B. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28932 · Cited by 19 · see citing works
Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression
Ma, F., Liu, Y., Hu, Z., Xue, Y., Liu, Z., Cai, G., Su, W., Zheng, Z., Xia, F., Yan, X., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000042 · Cited by 19 · see citing works
Nonspecific native elution of proteins and mumps virus in immunoaffinity chromatography
Brgles, M., Sviben, D., Forčić, D., & Halassy, B. (2016) · Journal of Chromatography A · doi:10.1016/j.chroma.2016.04.022 · Cited by 19 · see citing works
Su, Q., Sena‐Esteves, M., & Gao, G. (2020) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot095604 · Cited by 19 · see citing works
Zanker, J., Lázaro-Petri, S., Hüser, D., Heilbronn, R., & Savy, A. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.182 · Cited by 18 · see citing works
Recent advances in upstream process development for production of recombinant adeno‐associated virus
Ou, J., Tang, Y., Xu, J., Tucci, J., Borys, M., & Khetan, A. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28545 · Cited by 17 · see citing works
Elkouby, L., Armour, S. M., Toso, R., DiPietro, M. A., Davidson, R. J., Nguyen, G. N., Willet, M., Kutza, S., Silverberg, J., Frick, J. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.005 · Cited by 17 · see citing works
Crucial aspects for maintaining rAAV stability
Lengler, J., Gavrila, M., Brandis, J., Palavra, K., Dieringer, F., Unterthurner, S., Fuchsberger, F. F., Kraus, B., & Bort, J. A. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-79369-0 · Cited by 16 · see citing works
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Mével, M., Pichard, V., Bouzelha, M., Álvarez‐Dorta, D., Lalys, P.-A., Provost, N., Allais, M., Mendes, A., Landagaray, E., Ducloyer, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101187 · Cited by 16 · see citing works
Ramy, S., Ueda, Y., Nakajima, H., Hiroi, M., Hiroi, Y., Torisu, T., & Uchiyama, S. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.10.022 · Cited by 16 · see citing works
Chng, K., Larsen, S. R., Zhou, S., Wright, J. F., Martiniello‐Wilks, R., & Rasko, J. E. J. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.990 · Cited by 16 · see citing works
Self-citationReinauer, E., Grosso, S. S., Henz, S. R., Rabas, J. A., Rodenstein, C., Altrichter, J., Scholz, M., & Kemter, K. F. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.063 · Cited by 16 · see citing works
Meierrieks, F., Weltken, A., Pflanz, K. B., Pickl, A., Graf, B., & Wolff, M. W. (2024) · Biotechnology Journal · doi:10.1002/biot.202400430 · Cited by 15 · see citing works
Controlled inactivation of recombinant viruses with vitamin B2
Callahan, S. M., Wonganan, P., Obenauer-Kutner, L. J., Sutjipto, S., Dekker, J. D., & Croyle, M. A. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2007.10.027 · Cited by 15 · see citing works
Thermostability and in vivo performance of AAV9 in a film matrix
Doan, T. N. K., Le, M. D., Bajrovic, I., Celentano, L., Krause, C., Balyan, H. G., Svancarek, A., Mote, A., Tretiakova, A. P., Samulski, R. J., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00212-6 · Cited by 14 · see citing works
Lavender, H., Brady, K., Burden, F., Delpuech-Adams, O. E., Denise, H., Palmer, A., Perkins, H., Savic, B., Scott, S., Smith‐Burchnell, C., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05357-11 · Cited by 14 · see citing works
Self-citationChromatographic Purification of Virus Particles
Gagnon, P. (2009) · Wiley eBooks · doi:10.1002/9780470054581.eib583 · Cited by 14 · see citing works
Turco, F., Wegelius, A., Lind, O., Norrman, N., Magnusson, A.-C., Sund-Lundström, C., Norén, B., Hedberg, J. J., & Palmgren, R. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.010 · Cited by 13 · see citing works
Som, M., Gikanga, B., Kanapuram, V., & Yadav, S. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.03.024 · Cited by 13 · see citing works
A blueprint for TFF format selection: Hollow fibers and flat sheets for ultrafiltration of AAV
McCarney, L., Ravichandran, A. G., Tansey, S., Dango, M., & Marchand, N. (2025) · Separation and Purification Technology · doi:10.1016/j.seppur.2025.133064 · Cited by 12 · see citing works
Jarand, C. W., Baker, K., Petroff, M., Jin, M., & Reed, W. F. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00027 · Cited by 12 · see citing works
Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies
Kish, W. S., Lightholder, J., Zeković, T., Berrill, A., Roach, M. K., Wellborn, W. B., & Vorst, E. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28737 · Cited by 12 · see citing works
Implications of AAV affinity column reuse and vector stability on product quality attributes
Soni, H., Lako, I., Placidi, M., & Cramer, S. M. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28500 · Cited by 12 · see citing works
Lyophilization as an effective tool to develop AAV8 gene therapy products for refrigerated storage
Zhi, L., Chen, Y., Lai, K.-Y. (., Wert, J., Li, S., Wang, X., Tang, X. C., Shameem, M., & Liu, D. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123564 · Cited by 12 · see citing works
Leskovec, M., Raspor, A., Fujs, V., Mihevc, A., & Štrancar, A. (2023) · Electrophoresis · doi:10.1002/elps.202300038 · Cited by 11 · see citing works
Pathak, K., Perrotti, G., Rosa, S. J., Robinett, G., Kasper, L., Xia, Q., Escalante, C. R., & Gomes, F. P. (2025) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.5c00074 · Cited by 11 · see citing works
Scalable Production and Purification of Adeno-Associated Viral Vectors (AAV)
Blessing, D., Déglon, N., & Schneider, B. L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8730-6_17 · Cited by 11 · see citing works
Considerations for Buffering Agent Selection for Frozen rAAV2 Mediated Gene Therapy Products
Pandharipande, P. P., Bhowmik, T., & Singh, N. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.06.019 · Cited by 11 · see citing works
Fukuda, M., Takahashi, K., Takarada, T., Saito, S., & Tanaka, M. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.10.004 · Cited by 10 · see citing works
Rapid Quality Control Assessment of Adeno-Associated Virus Vectors Via Stunner
Yang, Q., Walton, R. W., Kudrolli, T. A., Denys, N., Lance, K. D., & Chang, A. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.0007 · Cited by 10 · see citing works
Purification of AAV8 through a scalable two-step monolithic chromatography approach
Nascimento, A., Faria, T. Q., Bollmann, F., Noverraz, M., Pressac, G., Roldão, A., Peixoto, C., & Silva, R. J. S. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.465586 · Cited by 9 · see citing works
Aponte, J. J., Barajas, D., Sterling, H. J., Aghajanirefah, A., Bardliving, C. L., Peltier, J., Shamlou, P. A., Roy, M., & Gold, D. (2020) · MicrobiologyOpen · doi:10.1002/mbo3.1136 · Cited by 9 · see citing works
- Authors
- Wright, J. F., Le, T., Prado, J., Bahr-Davidson, J., Smith, P. H., Zhen, Z., Sommer, J. M., Pierce, G. F., & Qu, G.
- Corresponding author
- Wright, J. Fraser
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 12
- Issue
- 1
- Pages
- 171-178
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2075785803
- Cited by
- 158
- References
- 24
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 16 · 2023: 20 · 2022: 9 · 2021: 17 · 2020: 9 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 4
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- recombinant adeno-associated virus type 2, ionic strength, vector purification, vector formulation, excipient screening, salt addition, freeze-thaw stability, nuclease digestion, transduction efficiency, gene therapy vectors
- MeSH terms
- Dependovirus, Deoxyribonucleases, Genetic Vectors, Humans, Osmolar Concentration, Scattering, Radiation, Temperature
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
